Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
venerdì, ottobre 23
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Eledon Pharmaceuticals Inc
ELDN
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$2.30
0.04
1.77%
Ult. Agg.: Oct 23, 4:25 AM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Eledon Pharmaceuticals Financials
Eledon Pharmaceuticals (ELDN) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Eledon Pharma Q2 EPS $(0.27) Misses $(0.16) Estimate
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.16) by 68.75 percent. This is a 107.69 percent decrease over losses of $(0.13) per share from
Benzinga Newsdesk
PRO
Eledon Pharma Q1 EPS $(0.33) Misses $(0.18) Estimate
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.18) by 83.33 percent. This is a 312.5 percent decrease over losses of $(0.08) per share from
Benzinga Newsdesk
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug
NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and plans accelerated execution in 2026.
Vandana Singh
PRO
Eledon Pharma Q4 EPS $(0.10) Beats $(0.18) Estimate
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.18) by 45.95 percent. This is a 84.38 percent increase over losses of $(0.64) per share from the
Benzinga Newsdesk
PRO
Eledon Pharma Q3 EPS $(0.21) Beats $(0.24) Estimate
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.24) by 11.39 percent. This is a 25 percent increase over losses of $(0.28) per share from the
Benzinga Newsdesk
Dow Dips Over 200 Points; Fluor Shares Slide After Q3 Results
Avi Kapoor
